Kornimate/medical-research-clean huggingface dataset:
immediate effect of whole-body vibration and walk in osteoporosis/osteopenia

Conditions: Osteoporosis

Summary: introduction: osteoporosis and osteopenia are common bone disorders, characterized by low bone mass, signs of bone deterioration and are responsible for typical bone fragility. physical activity is certainly a valid prevention tool because it contributes to a healthy energy balance, increasing muscle mass and providing beneficial effects in bone metabolism. stress induced by more vigorous activities such as weight lifting, increases the risk of injury, particularly in the elderly. therefore, alternative strategies with lower risk of injury are indicated such as whole body vibration and walk. objective: compare the effect whole body vibration and walking on muscular strength, balance and functional performance in the elderly with osteoporosis and osteopenia methods: it is a clinical trial study, controlled, parallel, randomized and blind, which will follow the guidelines established in the consolidated standards of reporting trials (consort). participants will be randomly distributed in 2 groups: the experimental group (gi) that will hold the training in the vibrating platform and the control group (gc) that will perform the walk, settling 1 treatment session. all participants will be subjected to the initial and final assessment.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of osteoporosis or osteopenia examination of bone densitometry; * patients without severe neurological disease, vascular disorders, labyrinthitis and blindness; * no use of gait auxiliaries; * no history of fractures of the lower limbs in the last year; * do not be an alcoholic inactive (0 to 5 points) or less active (6 to 11 points) accordance with the usual physical activity questionnaire (qafh). exclusion criteria: -patients who submit to hypertensive peak, nausea and dizziness during the training program.

Keywords: osteoporosis muscle strength postural balance vibration walking
chronic beta2-adrenergic stimulation and cardiac and skeletal muscle hypertrophy

Conditions: Muscle Hypertrophy in Healthy Young Men

Summary: studies in animals have shown that beta2-adrenoceptor activation with selective agonists regulates protein metabolism and muscle growth in skeletal and cardiac muscle tissue. these effects may be mediated by camp/pka dependent activation of several downstream sites that modulate protein synthesis and breakdown. while the role of beta2-adrenoceptor signaling is well-described in animals, it is inadequately explored in humans. the purpose of the study is thus to investigate the effect of chronic beta2-adrenergic stimulation (camp/pka-signaling) on muscle hypertrophy.


Eligibility criteria:
inclusion criteria: * physical active * non-smokers * non-asthmatics * no chronic diseases * informed consent exclusion criteria: * smoker * allergy towards study drug
recent techniques for diagnosing central venous catheter-related bloodstream infections in children

Conditions: Catheter-related Bloodstream Infection

Summary: removal of a central venous catheter (cvc) is often useful to prove its responsibility in a bloodstream infection. to avoid unnecessary removal of cvc, some catheter-spearing diagnostic methods have been recently developed. the aim of the study is to evaluate three catheter-spearing diagnostic methods in critically ill children: 1) the measurement of the differential time to positivity between a blood culture drawn from a peripherical vein and another one drawn through the cvc; 2) the exam of a blood sample drawn for the cvc and stained by acridine orange leucocyte cytospin test; 3) the semi-quantitative skin culture of the area around the insertion site of the cvc.

samples for the three techniques described above will be collected from the children admitted in pediatric intensive care unit with a cvc for more than 48 hours and with clinical or biological signs of systemic infection. any investigation required to determine the origin of the infection will be performed, according to physician's judgement. if the cvc is removed or changed on a guide wire, a quantitative culture of the distal segment will be performed. all the patients with a bloodstream infection and sampled according to the protocol will be included for statistical analysis. the physician and an independent medical expert will analyse if the bloodstream infection is cvc-related or not, according to the reference standard, by analysis of the clinical and bacteriological data, blinded towards the three studied techniques. the most optimal threshold will be determined and the sensibility, the specificity, the positive and negative predictable value of the three techniques will be calculated. then sensibility of these three techniques will be compared.

Eligibility criteria:
inclusion criteria: * age between 0 and 18 years. * presence of a central venous catheter for more than 48h (excepted umbilical catheter or peripherally inserted central catheters) * presence of at least one clinical or biological sign of systemic infection * parents are informed of the protocol and don't refuse the inclusion * prior inclusion in this study for the same bloodstream infection exclusion criteria:

Keywords: blood culture central venous catheter acridine orange leucocyte cytospin test semi-quantitative skin culture
a study of single and multiple doses of khk6640 in subjects with prodromal or mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of khk6640, given as a single dose and as multiple doses in patients with prodromal alzheimer's disease (ad) or mild to moderate ad.


Eligibility criteria:
inclusion criteria: * patients with prodromal ad or mild to moderate ad * clinical dementia rating (cdr) score of 0.5, 1.0, or 2.0 * have a cognitive impairment * low aβ and high tau in cerebrospinal fluid (csf) * mini mental state examination (mmse) score \> 16 at screening exclusion criteria: * previous active treatment with an ad immunotherapy in an investigational study * use of another investigational drug within 30 days of screening * history or presence of clinically significant seizures, brain trauma, transient ischemic attack, and/or cerebrovascular disease * presence of a neurological condition that could be contributing to cognitive impairment above and beyond that caused by the subject's ad * evidence of infection, tumor, or other clinically significant lesions that could indicate a dementia diagnosis other than ad
gallbladder stones in children and correlation with etiological factors

Conditions: Gallbladder Stone

Summary: aims of the study: the objective of this study is to estimate the correlation between etiological factors and postoperative histochemical analysis of pediatric gallbladder stones.

study design: a prospective, cohort study. duration of the study: the study starts from october 2024 to august 2025. place of the study: the study will be held in department of pediatric surgery in sohag university hospital. inclusion and exclusion criteria: inclusion criteria: age \<18 years . symptomatic gallbladder stones (biliary colic, fever, vomiting, positive murphy sign ) . congenital hemolytic anemia with gallbladder stones. asymptomatic patient with gallbladder stones \<5mm after medical treatment (ursodeoxycholic acid ) for 1year . imaging criteria ( large gallbladder stone \ 3mm ) either symptomatic or asymptomatic . exclusion criteria: age \>18 years. asymptomatic patients who improved after follow up and medical treatment . biliary anomaly as choledochal cyst , biliary stricture. common bile duct stones .

Eligibility criteria:
inclusion criteria: * inclusion criteria: age \<18 years . symptomatic gallbladder stones (biliary colic, fever, vomiting, positive murphy sign ) . congenital hemolytic anemia with gallbladder stones. asymptomatic patient with gallbladder stones \<5mm after medical treatment (ursodeoxycholic acid ) for 1year . imaging criteria ( large gallbladder stone \ 3mm ) either symptomatic or asymptomatic . exclusion criteria: * age \>18 years. asymptomatic patients who improved after follow up and medical treatment . biliary anomaly as choledochal cyst , biliary stricture. common bile duct stones .
developing a complex ex vivo endometrial tissue model to improve endometriosis care

Conditions: Endometriosis

Summary: endometriosis is a chronic gynaecological disease characterised by the growth of endometrium outside the uterus. it affects 10% of childbearing age women. there is no cure for endometriosis. hormonal treatments should be the first line therapy. the benefit-risk ratio of symptomatic treatment with hormone therapy varies greatly from one woman to another. the pathophysiology of endometriosis and the mechanisms of action of these treatments are still poorly understood. this may be due to the lack of an optimal experimental model for studying the disease. the aim of this project is to develop a complex ex vivo endometrial model recapitulating the organisation and properties of the human endometrium using innovative tissue bioengineering methods. this model will make it possible to develop a pre-clinical approach that predicts individual response to different types of hormonal treatment in order to optimise therapeutic choices and provide a better understanding of the effects of these treatments.


Eligibility criteria:
inclusion criteria: * female * people aged between 18 and 50 * person who has or has had hormonal contraceptive treatment * a person who has given written consent * person diagnosed with a benign gynaecological pathology not affecting the endometrium and requiring hysterectomy, hysteroscopy or laparoscopy or with a diagnosis of endometriosis and requiring laparoscopy or hysterectomy * person affiliated to the french social security exclusion criteria: * pregnant at the time of sampling or within 3 months prior to sampling * breast-feeding women * women undergoing physiological menopause * anyone who has received hormonal treatment with hormones other than steroids in the three months prior to sampling * anyone with a non-hormonal contraceptive intrauterine device (copper coil) * anyone with a personal history of cancer of the breast, ovary, endometrium or cervix * people with lynch syndrome * persons under legal protection (guardianship, curatorship) * persons deprived of their liberty by judicial or administrative decision * persons with a body mass index (bmi) of less than 18.5 or more than 30

Keywords: endometriosis tissue bioengineering hormonal therapies
icg distribution using nif imaging after iv injection of icg in benign and malignant breast cancer tissue.

Conditions: Breast Cancer.

Summary: the purpose of this study is to determine if nif fluoresent imaging is an effctive approch to detect the margine of the breast tumoral tissue.

primary objective: definition of the histological distribution (intravascular, extra vascular, in specific cells) of icg (pre-operatively intra-venously injected) at the level of tumoral and healthy tissues of breast cancer patients (and the potential of axillary lymph nodes found fluorescent). secondary objectives: evaluation of the ability of the fluorescence imaging to determine the tumor volume and, more specifically, the boundaries of tumor tissues which will be analyzed by the pathologist. analysis of the correlation between fluorescence and "margins" as defined operatively as tumor (microscopically by the pathologist).

Eligibility criteria:
inclusion criteria: * patients with histopathological diagnosis of breast cancer for which a mastectomy with axillary dissection is planned. * informed consent signed. exclusion criteria: * diagnosis of breast cancer established by lumpectomy or "macro-biopsy". * operation after neo-adjuvant chemotherapy, * age less than 18 years. * for pre-menopausal women, an operation planned for the second phase of their cycle. * inability to give informed consent. * history of allergy or hypersensitivity to the investigational product, iodine. * clinical or biological hyperthyroidism. * known "toxic" thyroid nodules or known autonomous (hyperfunctional) thyroid. * a reported pathological coronary artery disease. * creatinine \> 1.5 mg / dl. * during the 2 weeks before surgery, being on medications which are known to interfere with the icg (ie anticonvulsants, heparin and haloperidol). * pregnancy or breast feeding period.
accuracy of a newly developed mobile application versus the conventional method of cephalometric analysis in the diagnosis of dental and skeletal deformities among pre-adolescent patients

Conditions: Mobile Application; Cephalometric Analysis

Summary: this study aims to evaluate the accuracy of a newly developed mobile application versus the conventional method of cephalometric analysis in the diagnosis of dental and skeletal deformities among pre-adolescent patients.

a mobile application will be developed to help pedodontists in orthodontic diagnosis, and treatment of dentoalveolar, or skeletal deformations ,the mobile application will provide quick cephalometric analysis and therefore, offers rapid and accurate case diagnosis, reduces errors in tracing, measurement, and identification of the landmark. reference test: cephalometric analysis by the conventional method -trial design: diagnostic accuracy study

Eligibility criteria:
inclusion criteria: 1. digital lateral cephalometric radiographs of pre-adolescent patients (8-13) years old. 2. cephalogram of good quality with all landmarks clearly visible 3. presence of central incisors and first molars on cephalogram 4. cephalogram with teeth in maximum intercuspation exclusion criteria: -
cholecystectomy in patients with silent common bile duct stones

Conditions: Performing Cholecystectomy in Patients With Chronic Calcular Choleycystits

Summary: aim of this study is to evaluate the efficacy of performing only cholecystectomy in patients with asymptomatic common bile duct stones without dealing with common bile duct stones


Eligibility criteria:
inclusion criteria: * patients with asymptomatic common bile duct stones. * patients with normal bilirubin levels. * patients with normal alkaline phosphates level. exclusion criteria: * patients with history of jaundice. * patients with abnormal liver functions.

Keywords: cbd stones , cholecystectomy silent stones
efficacy of different anti-thrombotic strategies on the incidence of silent cerebral embolism after percutaneous left atrial appendage occlusion

Conditions: Atrial Fibrillation; Left Atrial Appendage Occlusion; Silent Cerebral Embolism

Summary: the primary objective of this investigation is to compare the efficacy of two different antithrombotic strategies after percutaneous laa occlusion with a watchman device on the prevention of silent cerebral embolism.

background left atrial appendage intervention is increasingly recognized as an alternative strategy for thromboembolism prophylaxis in af. theoretically, a complete occlusion of left atrial appendage may eliminate the possibility of embolism from the appendage. however, residual risk exists due to blood stasis and endothelial dysfunction in the atrial fibrillation state. this may raise an issue that whether we should and how to give the patients after appendage occlusion long-term antithrombotic therapy. meanwhile, patients with af have a high incidence of silent cerebral embolism (sce), which has similar impact with clinical stroke on cognition function. we hypothesized that the sce caused by micro embolism may act as part of the residual risk after appendage occlusion, thus, an optimal antithrombotic treatment to decrease the incidence of sce remains unclear. aim of this study the primary objective of this investigation is to compare the efficacy of two different antithrombotic strategies after percutaneous laa occlusion with a watchman device on the prevention of sce. the primary endpoint is incidence of sce detected by mri. the secondary endpoints are more than two new sce detected by mri, cognition function and composite endpoint of all-cause mortality, clinical thromboembolic events and major bleeding events. design this is a randomized, prospective, multicenter design. we aim to include 150 patients 45 days after successful laac with watchman device. patients are randomized in a 1:1 fashion into two arms: standard antiplatelet therapy and half-dose noac. follow-up duration of this study is 12 months. the 1-year routine follow-up strategy included dw-mri scans performed approximately 90 days, 180 days, and 365 days post-procedure.

Eligibility criteria:
inclusion criteria: 1. af patients over 18 years old 2. patients had undergone left atrial appendage occlusion with watchman device and confirmed no significant peri-device leak or drt at the 45-day ct 3. patients have a history of ischemic thromboembolic events or have cha2ds2-vasc score ≥3 exclusion criteria: 1. patients with an indication of long-term antiplatelet therapy other than laao at the time of enrollment (eg, acs, intracranial vascular stenosis≥75%) 2. absolute contraindications to oac 3. absolute contraindications to anti-platelet therapy 4. contraindications to mr or unwilling to receiving mr 5. patients with clinical thromboembolicor major bleeding events within 45 days after laa occlusion

Keywords: atrial fibrillation left atrial appendage occlusion silent cerebral embolism oral anticoagulation antiplatelet therapy
health related quality of life after surgery and oncological treatment of colorectal liver metastases

Conditions: Metastasis; Quality of Life

Summary: the purpose of this trial is to study health related quality of life (hqol)after resection of colorectal liver metastases combined with perioperative chemotherapy. the investigators want to study if an aggressive, life prolonging and multimodal treatment can be defended from a quality of life perspective.

background: hepatic resection is the only treatment with potential curative intent for patients having colorectal liver metastases. combined with chemotherapy, the overall 5-year survival is 40-50%. the disease free 5-year survival is about 20%, and about 70% of resected patients experience recurrence from their disease. even if surgery is superior all other treatments, most patients will finally die from their cancer. however; surgery contributes by adding years of life, and for a minority, a disease free life. there has been much effort to study predictors for outcome after surgery, but little has been focused on quality of life following this treatment. method: eortc validated questionnaire (european organisation research of treatment of cancer) version qlq-c30 (3.0) and qlq lmc21. the patients fill out the questionnaire before surgery as a baseline, and then after 3,6 and 12 months after surgery. the investigators also register important clinicopathological data about each patient prospectively.

Eligibility criteria:
inclusion criteria: * liver metastasis from colorectal cancer * resectability, with intension of r0 resection * no macroscopic tumor left after surgery * patients with combined resectable extrahepatic tumors are also included. * patients must complete the questionnaire before the operation. exclusion criteria: * drop out of questionnaire after surgery * patients found to be irresectable during the operation or where macroscopic tumor tissue are left behind.

Keywords: health related quality of life colorectal liver metastasis surveillance
a study of erdafitinib in participants with advanced solid tumors and fibroblast growth factor receptor (fgfr) gene alterations

Conditions: Advanced Solid Tumor

Summary: the purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (orr) in adult and pediatric participants with advanced solid tumors with fibroblast growth factor receptor (fgfr) alterations (mutations or gene fusions). it will also evaluate orr in pediatric participants with advanced solid tumors and fgfr alterations.

erdafitinib is a selective and potent pan fgfr 1-4 inhibitor with demonstrated clinical activity in participants with metastatic urothelial cancer and cholangiocarcinoma identified to have alterations in the fgfr pathway. this study targets the underlying altered biology of fgfr-driven tumors irrespective of solid tumor histology subtype. the study consists of screening phase, treatment phase and the post treatment follow-up phase (from the end of treatment visit until the participant has died, withdraws consent, is lost to follow-up, or the end of study, whichever comes first). end of study is considered as the time when the last participant receives the last dose of study drug on the study and either all pediatric participants are off study or until the most recently enrolled pediatric participant still participating in the study has 6 months of follow-up, whichever occurs first. currently this study is recruiting pediatric participants only.

Eligibility criteria:
inclusion criteria: * histologic demonstration of an unresectable, locally advanced, or metastatic solid tumor malignancy with an fibroblast growth factor receptor (fgfr) mutation or fgfr gene fusion * measurable disease * participant must have received at least one prior line of systemic therapy in the advanced, unresectable, or metastatic setting; or is a child or adolescent participant with a newly-diagnosed solid tumor and no acceptable standard therapies * documented progression of disease, defined as any progression that requires a change in treatment, prior to full study screening exclusion criteria: * has had prior chemotherapy, targeted therapy, or treatment with an investigational anticancer agent within 15 days or less than or equal to (\<=) 5 half-lives of the agent (whichever is longer) and up to a maximum of 30 days before the first dose of erdafitinib * the presence of fgfr gatekeeper and resistance mutations * histologic demonstration of urothelial carcinoma * hematologic malignancy (i.e., myeloid and lymphoid neoplasms * for non-small cell lung cancer participants only: pathogenic somatic mutations or gene fusions in the following genes: egfr, alk, ros1, ntrk, braf v600e and kras * active malignancies other than for disease requiring therapy
maintenance bee-venom immunotherapy administered at 6-month intervals does not protect against re-stings

Conditions: Venom Allergy

Summary: maintenance venom immunotherapy administered at 6-month intervals to bee-venom allergic patients failed to provide protection from systemic reactions after sting challenges. these patients should continue their immunotherapy at 1-3 month intervals.

background: the intervals at which maintenance venom immunotherapy (mvit) is administered have been progressively extended over the years. objective: to examine whether the administration of bee venom (bv) maintenance dose (md) at 6-month interval is safe and efficacious. methods: the usual 3-month interval at which venom allergic patients were receiving their mvit was gradually extended to 6 months. systemic reactions (srs) to immunotherapy injections or to field stings were regularly recorded. bv allergic patients were deliberately sting-challenged after reaching the 6-month interval.

Eligibility criteria:
inclusion criteria: * venom allergy exclusion criteria: * none